Singapore markets closed

BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
6.66+0.24 (+3.74%)
At close: 04:00PM EDT
6.65 -0.01 (-0.15%)
Pre-market: 09:28AM EDT

BioCryst Pharmaceuticals, Inc.

4505 Emperor Boulevard
Suite 200
Durham, NC 27703
United States
919 859 1302
https://www.biocryst.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees536

Key executives

NameTitlePayExercisedYear born
Mr. Jon P. StonehouseCEO, President & Executive Director1.23M647.14k1961
Mr. Anthony J. DoyleSenior VP, CFO & Interim Principal Accounting Officer845.93kN/A1980
Ms. Alane P. BarnesSenior VP, Chief Legal Officer & Corporate Secretary794.75kN/A1966
Dr. Helen M. Thackray FAAP, M.D.Chief Research & Development Officer976.15kN/A1968
Mr. Charles K. GayerSenior VP & Chief Commercial Officer794.12kN/A1971
Mr. John D. BluthChief Communications OfficerN/AN/A1973
Ms. Stephanie AngeliniChief People OfficerN/AN/AN/A
Dr. William P. Sheridan MBBSChief Development Officer & Interim Chief Medical Officer784.09k4.4M1955
Dr. Yarlagadda S. Babu Ph.D.Chief Discovery Officer691.45k1.25M1953
Ms. Jinky Ang RosselliChief Data & Insights OfficerN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Corporate governance

BioCryst Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 May 2024 is 6. The pillar scores are Audit: 8; Board: 3; Shareholder rights: 8; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.